open access

Vol 19, No 3 (2012)
Review articles
Published online: 2012-05-28
Get Citation

Antiarrhythmic potential of aldosterone antagonists in atrial fibrillation

Rafał Dąbrowski, Hanna Szwed
Cardiol J 2012;19(3):223-229.

open access

Vol 19, No 3 (2012)
Review articles
Published online: 2012-05-28

Abstract

Upstream therapy is the promising issue in the treatment of atrial fibrillation (AF) especially in patients with arterial hypertension and heart failure. The possible beneficial effects of renin– –angiotensin–aldosterone system blockade with ACE-inhibitors and angiotensin receptor antagonists in AF prevention have been demonstrated in experimental and clinical studies. There is growing mass of evidence, from both theoretical and experimental research studies, to suggest that upstream therapy using spironolactone or eplerenone may reduce the deleterious effect of excess aldosterone secretion and further modify the environment of AF including inhibition of atrial muscle fibrosis. It refers to patients with different forms of AF, including chronic AF. Aldosterone antagonists treatment may be a simple and valuable additional option in low-risk, hypertensive and heart failure patients in primary and secondary prevention of refractory paroxysmal and persistent AF.

Abstract

Upstream therapy is the promising issue in the treatment of atrial fibrillation (AF) especially in patients with arterial hypertension and heart failure. The possible beneficial effects of renin– –angiotensin–aldosterone system blockade with ACE-inhibitors and angiotensin receptor antagonists in AF prevention have been demonstrated in experimental and clinical studies. There is growing mass of evidence, from both theoretical and experimental research studies, to suggest that upstream therapy using spironolactone or eplerenone may reduce the deleterious effect of excess aldosterone secretion and further modify the environment of AF including inhibition of atrial muscle fibrosis. It refers to patients with different forms of AF, including chronic AF. Aldosterone antagonists treatment may be a simple and valuable additional option in low-risk, hypertensive and heart failure patients in primary and secondary prevention of refractory paroxysmal and persistent AF.
Get Citation

Keywords

aldosterone antagonists; atrial fibrillation

About this article
Title

Antiarrhythmic potential of aldosterone antagonists in atrial fibrillation

Journal

Cardiology Journal

Issue

Vol 19, No 3 (2012)

Pages

223-229

Published online

2012-05-28

Bibliographic record

Cardiol J 2012;19(3):223-229.

Keywords

aldosterone antagonists
atrial fibrillation

Authors

Rafał Dąbrowski
Hanna Szwed

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl